Lansoprazole


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult: PO Peptic ulcer 30 mg once daily for 2-4 weeks (duodenal ulcer) or for 4-8 weeks (gastric ulcer). Zollinger-Ellison syndrome Initial: 60 mg once daily, may be adjusted up to 180 mg/day according to response. Daily doses >120 mg should be given in 2 divided doses. Gastro-oesophageal reflux disease 15 mg or 30 mg once daily for 4 weeks, may be adjusted according to response. NSAID-associated ulceration 30 mg once daily for 4-8 weeks. Prophylaxis of NSAID-induced ulcers 15-30 mg once daily. Eradication of H. pylori associated with peptic ulcer disease As triple therapy: 30 mg bid for 7-14 days in combination with clarithromycin and with either amoxicillin or metronidazole, or in combination with amoxicillin and metronidazole. As dual therapy: 30 mg tid for 14 days in combination with amoxicillin. Reflux oesophagitis Treatment: 30 mg once daily for 4-8 weeks. Prophylaxis: 15 mg once daily, may be increased up to 30 mg once daily if necessary. IV Erosive oesophagitis 30 mg once daily via infusion over 30 minutes for up to 7 days until oral therapy is possible for a total of 6-8 weeks
Administration
Should be taken on an empty stomach (i.e. At least one hour before food or two hours after food).
Contraindications
Concomitant use with rilpivirine and atazanavir.
Special Precautions
Patients with gastric malignancy, risk factors for reduced vitamin B12 absorption or reduced body stores; risk of osteoporosis. Moderate to severe hepatic impairment. Elderly. Pregnancy and lactation. CYP2C19 ultrarapid metabolisers. Patient Counselling This drug may cause dizziness or visual disturbances, if affected, do not drive or operate machinery. Monitoring Parameters Monitor serum Mg levels at baseline and periodically thereafter; CBC, LFTs, renal function tests, serum gastrin levels. Assess for signs and symptoms of bone fractures and Clostridium difficile-associated diarrhoea (CDAD).
Adverse Reactions
Significant: Hypomagnesaemia, osteoporosis-related fractures, fundic gland polyps, subacute cutaneous lupus erythematosus, SLE, interstitial nephritis, Clostridium difficile-associated diarrhoea, gastrointestinal infections (e.g. Salmonella, Campylobacter), vitamin B12 deficiency (long-term therapy). Blood and lymphatic system disorders: Thrombocytopenia, leucopenia, eosinophilia. Eye disorders: Visual disturbances. Gastrointestinal disorders: Diarrhoea, abdominal pain, constipation, nausea, dyspepsia, flatulence, dry mouth or throat. Rarely, colitis, stomatitis. General disorders and administration site conditions: Fatigue, inj site pain and reactions (IV). Hepatobiliary disorders: Increased liver enzymes. Immune system disorders: Urticaria. Metabolism and nutrition disorders: Peripheral oedema. Musculoskeletal and connective tissue disorders: Arthralgia, myalgia. Nervous system disorders: Headache, dizziness, vertigo, somnolence, paraesthesia. Psychiatric disorders: Depression, insomnia, confusion. Reproductive system and breast disorders: Gynaecomastia. Skin and subcutaneous tissue disorders: Rash, pruritus, eczema.
ROUTE(S) : PO: B
ROUTE(S) : Parenteral: C
Drug Interactions
May decrease plasma concentrations of rilpivirine, atazanavir and nelfinavir. Increased INR and prothrombin time with warfarin. May diminish the therapeutic effect of clopidogrel. May increase exposure of digoxins. May reduce absorption of ketoconazole and itraconazole. May increase risk of hypomagnesaemia with diuretics. May increase plasma concentrations of methotrexate and tacrolimus. May reduce serum concentration of theophylline. Reduced bioavailability with sucralfate and antacids. Increased plasma concentration with CYP2C19 inhibitor (e.g. fluvoxamine). Reduced serum levels with CYP2C19 and CYP3A4 inducers (e.g. rifampicin).
ATC Classification
A02BC03 - lansoprazole ; Belongs to the class of proton pump inhibitors. Used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).
Disclaimer: This information is independently developed by CIMS based on lansoprazole from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in